MedTrace Logo

Oxytocin-augmented Cognitive-behavioral Group-based Short-term Intervention for Loneliness

NCT04137432 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-10-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical potential of oxytocin (OT) as an adjunct to a cognitive-behavioral group-based shortterm intervention for participants suffering from loneliness.

Conditions

  • Loneliness

Interventions

DRUG

Oxytocin nasal spray

Intranasal administration of 24 international units oxytocin.

DRUG

Placebo

The placebo nasal sprays contains identical ingredients except for the peptide itself.

Sponsors & Collaborators

  • The German-Israeli Foundation for Scientific Research and Development

    collaborator OTHER

  • Prof. Simone Shamay-Tsoory, University of Haifa

    collaborator UNKNOWN

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Rene Hurlemann, MSc, MD, PhD · University of Oldenburg

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2020-09-30
Completion
2020-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04137432 on ClinicalTrials.gov